Mirabegron: risk of severe hypertension

Mirabegron (Betmiga) is associated with a risk of severe hypertension, cerebrovascular and cardiac events, and is now contraindicated in patients with severe uncontrolled hypertension, the MHRA has advised.

Mirabegron is used in the management of urinary frequency, urgency and incontinence in overactive bladder syndrome.
Mirabegron is used in the management of urinary frequency, urgency and incontinence in overactive bladder syndrome.

Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg) and should be used with caution in patients with stage 2 hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).

Further information
View Betmiga drug record
MHRA Drug Safety Update
Manufacturer: Astellas Pharma

Cases of severe hypertension, including hypertensive crisis associated with reports of transient ischaemia attack or stroke, have been reported in patients treated with mirabegron. Healthcare professionals should measure blood pressure before and throughout treatment, especially in patients with pre-existing hypertension. 

All suspected adverse reactions associated with mirabegron should be reported in accordance with the MHRA Yellow Card Scheme.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.

Researchers query safety of delaying antibiotics for UTI in elderly

Researchers query safety of delaying antibiotics for UTI in elderly

Delaying or withholding antibiotics for symptoms of...